ReviewBMC anesthesiology2026
Allergic reaction to nalbuphine administration in a pre-adolescent patient: a case report and literature review.
Review in BMC anesthesiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundNalbuphine is synthetic agonist-antagonist opioid compound. Allergic reactions to nalbuphine hydrochloride are exceedingly rare. We present a case of hypersensitivity reaction to nalbuphine in a pre-adolescent patient. CASE PRESENTATION: A male patient, aged 11 years, underwent general anesthesia for the correction of congenital strephexopodia. Nalbuphine hydrochloride was administered as part of the postoperative analgesia regimen. However, the patient subsequently developed an allergic reaction characterized by pulmonary edema, wheezing, tachycardia and cutaneous rash. Prompt initiation of anti-allergic therapy resulted in significant clinical improvement. The patient was subsequently transferred to the general ward following complete resolution of symptoms.
conclusionsThis case report highlights a hypersensitivity reaction to nalbuphine in pre-adolescent patient, manifesting with both cutaneous and respiratory symptoms. To improve the safety profile of nalbuphine in pre-adolescent populations, further research is necessary to elucidate the underlying mechanisms of such adverse reactions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.